These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 21942527)
1. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Lessnick SL; Ladanyi M Annu Rev Pathol; 2012; 7():145-59. PubMed ID: 21942527 [TBL] [Abstract][Full Text] [Related]
2. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302 [TBL] [Abstract][Full Text] [Related]
3. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
4. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381 [TBL] [Abstract][Full Text] [Related]
6. FOXM1 is an oncogenic mediator in Ewing Sarcoma. Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673 [TBL] [Abstract][Full Text] [Related]
7. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma. Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119 [TBL] [Abstract][Full Text] [Related]
8. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells. El Beaino M; Liu J; Wasylishen AR; Pourebrahim R; Migut A; Bessellieu BJ; Huang K; Lin PP BMC Cancer; 2020 Jan; 20(1):3. PubMed ID: 31898537 [TBL] [Abstract][Full Text] [Related]
9. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma. Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588 [TBL] [Abstract][Full Text] [Related]
10. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784 [TBL] [Abstract][Full Text] [Related]
11. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis. Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416 [TBL] [Abstract][Full Text] [Related]
12. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076 [TBL] [Abstract][Full Text] [Related]
13. Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone. Park H; Turkalo TK; Nelson K; Folmsbee SS; Robb C; Roper B; Azuma M Cell Cycle; 2014; 13(15):2391-9. PubMed ID: 25483190 [TBL] [Abstract][Full Text] [Related]
14. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530 [TBL] [Abstract][Full Text] [Related]
15. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296 [TBL] [Abstract][Full Text] [Related]
16. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942 [TBL] [Abstract][Full Text] [Related]
17. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro. Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994 [TBL] [Abstract][Full Text] [Related]
18. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308 [TBL] [Abstract][Full Text] [Related]
19. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061 [TBL] [Abstract][Full Text] [Related]
20. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth. Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]